OncoCyte Corporation
OCX
$2.73
$0.083.02%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 80.09% | -148.36% | -197.86% | 50.38% | 42.92% |
| Total Depreciation and Amortization | -12.79% | 65.59% | 4.29% | -2.69% | 3.08% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -95.25% | 278.13% | 1,377.98% | -115.08% | -66.43% |
| Change in Net Operating Assets | 9.92% | -57,850.00% | 99.83% | -215.70% | 299.80% |
| Cash from Operations | -9.41% | 3.55% | 7.14% | -56.08% | 13.43% |
| Capital Expenditure | -43.46% | -145.98% | 54.45% | -695.83% | 90.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -46.19% | -141.38% | 54.45% | -695.83% | -123.30% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -19.51% | 4.65% | -160.61% | -- | -- |
| Issuance of Common Stock | 143.08% | 66,505.56% | -99.89% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | 100.00% | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 54.49% | -472.19% | 65.24% | -- | -- |
| Cash from Financing | 163.52% | 4,349.80% | -102.59% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 324.67% | 189.48% | -260.22% | 195.43% | 11.42% |